OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema, ...
EMBRACE reported 12-month suppression rates of 94% (IV N6LS+CAB LA), 82% (SC), and 88% (oral SOC), with no virologic failures and no new clinically significant AEs after month 6. Presentations focused ...
All titles, abstracts, photos and YouTube presentations will need your research mentor’s approval prior to submitting your abstract. The abstract will be open to public viewing. Submit your abstract ...
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster ...
STAMFORD, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation ...
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the presentation of three abstracts related to the development ...
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results